title: HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
authors.forename: E
authors.initials: E
authors.lastname: Florence
authors.forename: S
authors.initials: S
authors.lastname: De Wit
authors.forename: A
authors.initials: A
authors.lastname: Castagna
authors.forename: E
authors.initials: E
authors.lastname: Ribera
authors.forename: A
authors.initials: A
authors.lastname: Hill
authors.forename: H
authors.initials: H
authors.lastname: Vanaken
authors.forename: Y
authors.initials: Y
authors.lastname: van Delft
authors.forename: S
authors.initials: S
authors.lastname: Marks
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D000069454:Darunavir; D004334:Drug Administration Schedule; D005260:Female; D006678:HIV / Q000235:genetics / Q000302:isolation & purification; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011724:Pyridazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood*; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; C451734:etravirine; D000068898:Raltegravir Potassium; D019438:Ritonavir; D000069454:Darunavir